PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript Summary
PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript Summary
Net loss improved significantly from $3.7 million last year to $2.2 million this quarter.The following is a summary of the PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript:
以下是PetVivo控股有限公司（PETV）2025年第二季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
PetVivo reported a sequential revenue growth of 62% in the fiscal second quarter, primarily driven by a 147% increase in distributor sales.
The company achieved a gross profit margin of 89.5%.
Net loss improved significantly from $3.7 million last year to $2.2 million this quarter.
Operating expenses declined by 25% due to strategic company-wide reduction and restructuring programs.
PetVivo報告稱，第二財季收入連續增長62％，這主要是由分銷商銷售額增長147％推動的。
該公司實現了89.5％的毛利率。
淨虧損從去年的370萬美元大幅增加到本季度的220萬美元。
由於全公司的戰略裁員和重組計劃，運營費用下降了25％。
Business Progress:
業務進展：
PetVivo expanded the distribution of its flagship product, Spryng, which has now reached over 800 clinics across all 50 states.
New clinical trials, including an elbow study for dogs with osteoarthritis, are underway, enhancing the product's validation and adoption.
Significant staffing increases in sales and marketing roles have been made to support growth, especially aimed at the companion animal market.
PetVivo participated in major veterinary conferences and events, boosting visibility and advocacy for its Spryng product among veterinary professionals.
PetVivo擴大了其旗艦產品Spryng的分銷範圍，該產品現已覆蓋所有50個州的800多家診所。
新的臨床試驗，包括一項針對患有骨關節炎的狗的肘部研究，正在進行中，這加強了該產品的驗證和採用率。
爲了支持增長，銷售和營銷職位的人員配置已大幅增加，尤其是針對伴侶動物市場的增長。
PetVivo參加了大型獸醫會議和活動，提高了其Spryng產品在獸醫專業人員中的知名度和知名度。
Opportunities:
機會：
The expansion into the companion animal market, a significantly larger market segment, aims at driving future revenue growth.
Continued collaboration with leading R&D companies, like Orthobiologic Innovations, for product development and clinical trials to enhance product adoption.
向伴侶動物市場（一個顯著擴大的細分市場）的擴張旨在推動未來的收入增長。
繼續與Orthobiologic Innovations等領先研發公司合作，進行產品開發和臨床試驗，以提高產品採用率。
Risks:
風險：
Transition from smaller equine markets to companion animal markets involves risk of market acceptance and operational adjustments.
從小型馬匹市場向伴侶動物市場的過渡涉及市場接受和運營調整的風險。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
